DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Longview Innovation Corp.
Longview Innovation Corp.
Institutional venture firm · probableWilmington, DElongviewinnovation.comSEC registered investment adviser
Longview Innovation is cultivating a new era of innovation with groundbreaking science that will challenge the status quo and transform the future.
venture manager, reported GAV $125M across 5 vehicles
Importance
31
moderate
Active deployment
30
moderate
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
12
low
Identity and regulatory footprint
- Headquarters
- Wilmington, DEadviserinfo.sec.gov
- Office address
- 3411 SILVERSIDE RD, BAYNARD BUILDING, SUITE 104, Wilmington, DE, 19810adviserinfo.sec.gov
- Business phone
- 302-526-1610adviserinfo.sec.gov
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Oct 18, 2024
- Private funds reported
- 5 (4 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $125Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $125Mthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 8
- Owners on Schedule A
- Hard Science Investment Management LLC (Owner), E
- business email
- hello@longviewinnovation.comlongviewinnovation.compublished by the subject
- business phone
- 302-526-1610adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
11 observed deals
Stated (the firm’s website)
- Sectors
- biotech, hardware, robotics, industrial
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 82%Biotechnology 9%Other Technology 9%
lead rate n/afollow-on rate n/anew logos, 12 months 11
Funds and vehicles
5 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| IPG USA Sco LP | Fund | 2021 adv first reported | Mature | $7.6M Oct 18, 2024 | 1 | unknown | unknown |
| CT Spv Investment LP | SPV or co-invest vehicle · ADV: Private Equity Fund | 2021 form d first sale | Mature | $1.1M Oct 18, 2024 | 4 | $3.1M of $3.1M | Feb 26, 2021 |
| UL Spv Investment LLC | SPV or co-invest vehicle | 2021 adv first reported | Mature | $0 Oct 18, 2024 | 1 | unknown | unknown |
| Hard Science Spv Investment LLC | SPV or co-invest vehicle | 2020 form d first sale | Mature | $517,954 Oct 18, 2024 | 1 | $250,000 of $250,000 | Feb 26, 2021 |
| IPG Cayman LP | Feeder or parallel | 2018 form d first sale | Harvest | $116M Oct 18, 2024 | 14 | $158M | Mar 9, 2021 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
14 current, 3 departed
Dimitri Galitzine
Board or advisoryPortfolio Advisor
Joseph Carroll
Board or advisoryPortfolio Advisor
David Parke
PartnerInvestment Partner
Jason Smith
PartnerManaging Director
Michael Burychka
PartnerManaging Director
Michael Robert Burychka
PartnerOwner · since Nov 1, 2021
Will Meldrum
PartnerInvestment Partner
Brandon J Fleischman
Platform and operationsChief Legal Officer · since Jan 1, 2019
Katie Messner
Platform and operationsDirector, Portfolio Operations
Maxwell Robert Baker
Platform and operationsChief Compliance Officer · since Aug 1, 2021
Craig J Schortzmann
PrincipalDirector · since Apr 1, 2019
David Graham Baynes
PrincipalDirector · since Dec 1, 2016
Gregory Simon Smith
PrincipalDirector · since Nov 1, 2021
Mark Vivian Houghton-Berry
PrincipalDirector · since Sep 1, 2024
3 departed (kept with end dates)
- Alan James Aubrey · Director · Dec 1, 2016 to Nov 24, 2021 Inference
- Emily Tamara Janvey · Director · Jan 1, 2021 to Mar 26, 2024 Inference
- Varun Chandra · Director · Feb 1, 2021 to Oct 18, 2024 Inference
Investments on record
11 edges, 11 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
3 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
19 dated events
- Sep 16, 2026Abmeta Therapeutics Antibodies to novel targets in cancer metastasis. no longer listed on Longview Innovation Corp.'s portfolio pageRemoved from portfolio pagePortfolioInferenceAbmeta Therapeutics Antibodies to novel targets in cancer metastasis.Venture organization websites (about, team, portfolio, thesis, news pages)
- Oct 18, 2024Varun Chandra (Director) no longer on Schedule A of Longview Innovation Corp.
- Sep 1, 2024Mark Vivian Houghton-Berry joined Schedule A of Longview Innovation Corp. as Director
- Mar 26, 2024Emily Tamara Janvey (Director) no longer on Schedule A of Longview Innovation Corp.
- Nov 24, 2021Alan James Aubrey (Director) no longer on Schedule A of IP Group, Inc.
- Nov 1, 2021Gregory Simon Smith joined Schedule A of IP Group, Inc. as Director
- Sep 3, 2021CT Spv Investment LP first reported on Form ADV by IP Group, Inc. (Private Equity Fund), GAV $3,100,000Fund first reported on Form ADVFundsFactCT Spv Investment LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Aug 1, 2021Maxwell Robert Baker joined Schedule A of IP Group, Inc. as Chief Compliance Officer
- Mar 29, 2021IPG USA Sco LP first reported on Form ADV by IP Group, Inc. (Venture Capital Fund), GAV $3,000,000Fund first reported on Form ADVFundsFactIPG USA Sco LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2021UL Spv Investment LLC first reported on Form ADV by IP Group, Inc. (Venture Capital Fund), GAV $2,000,003Fund first reported on Form ADVFundsFactUL Spv Investment LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2021Hard Science Spv Investment LLC first reported on Form ADV by IP Group, Inc. (Venture Capital Fund), GAV $250,000Fund first reported on Form ADVFundsFactHard Science Spv Investment LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Feb 1, 2021Varun Chandra joined Schedule A of IP Group, Inc. as Director
- Jan 1, 2021Emily Tamara Janvey joined Schedule A of IP Group, Inc. as Director
- Apr 1, 2019Craig J Schortzmann joined Schedule A of IP Group, Inc. as Director
- Jan 1, 2019Brandon J Fleischman joined Schedule A of IP Group, Inc. as Chief Compliance Officer
- Dec 20, 2018IP Group, Inc. first filed Form ADV (ERA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Dec 20, 2018IPG Cayman LP first reported on Form ADV by IP Group, Inc. (Private Equity Fund), GAV $90,300,000Fund first reported on Form ADVFundsFactIPG Cayman LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Dec 1, 2016Alan James Aubrey joined Schedule A of IP Group, Inc. as Director
- Dec 1, 2016David Graham Baynes joined Schedule A of IP Group, Inc. as Director
Classification history
- Sep 12, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $125M across 5 vehicles
Evidence
39 observations from 2 sources